Brown, K. T., Do, R. K., Gonen, M., Covey, A. M., Getrajdman, G. I., Sofocleous, C. T., … Abou-Alfa, G. K. (2016). Trans-arterial embolization for hepatocellular carcinoma: Doxorubicin is not necessary. Translational Cancer Research, 5, S1299–S1301. https://doi.org/10.21037/tcr.2016.11.60

Brown, K. T., R. K. Do, M. Gonen, A. M. Covey, G. I. Getrajdman, C. T. Sofocleous, W. R. Jarnagin, et al. “Trans-arterial embolization for hepatocellular carcinoma: Doxorubicin is not necessary.” Translational Cancer Research 5 (January 1, 2016): S1299–1301. https://doi.org/10.21037/tcr.2016.11.60.

Brown KT, Do RK, Gonen M, Covey AM, Getrajdman GI, Sofocleous CT, et al. Trans-arterial embolization for hepatocellular carcinoma: Doxorubicin is not necessary. Translational Cancer Research. 2016 Jan 1;5:S1299–301.

Brown, K. T., et al. “Trans-arterial embolization for hepatocellular carcinoma: Doxorubicin is not necessary.” Translational Cancer Research, vol. 5, Jan. 2016, pp. S1299–301. Scopus, doi:10.21037/tcr.2016.11.60.

Brown KT, Do RK, Gonen M, Covey AM, Getrajdman GI, Sofocleous CT, Jarnagin WR, D’Angelica MI, Allen PJ, Erinjeri JP, Brody LA, Solomon SB, Schwartz LH, DeMatteo RP, Abou-Alfa GK. Trans-arterial embolization for hepatocellular carcinoma: Doxorubicin is not necessary. Translational Cancer Research. 2016 Jan 1;5:S1299–S1301.